Role of thyroid-stimulating blocking antibody in patients who developed hypothyroidism within one year after 131 I treatment for Graves' disease
| Autor: | Hiroshi Fukazawa, Yoshinori Kiso, Naoki Nakazato, Noriyo Sayama, Keishi Abe, Hironobu Hori, Yoshihiko Aizawa, Katsumi Yoshida, Jun-ichi Tani, Nobuko Kaise |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
endocrine system
medicine.medical_specialty endocrine system diseases business.industry Endocrinology Diabetes and Metabolism Graves' disease Thyroid Levothyroxine medicine.disease Endocrinology medicine.anatomical_structure Internal medicine Immunopathology Blocking antibody medicine Thyroid Stimulating Immunoglobulin Euthyroid Thyroid function business medicine.drug |
| Zdroj: | Clinical Endocrinology. 48:17-22 |
| ISSN: | 0300-0664 |
| Popis: | OBJECTIVE We recently reported that thyroid-stimulating blocking antibody (TSBAb) may not contribute to the development of hypothyroidism more than six years after 131I treatment. In the present study, we attempted to determine whether hypothyroidism that develops within a shorter period of time following 131I therapy is associated with TSBAb. DESIGN Retrospective study. PATIENTS Sera were obtained from 8 patients who developed hypothyroidism within 6 months after 131I therapy (Group 1), 8 patients who became euthyroid one year after 131I therapy (Group 2), and 7 patients who developed transient hypothyroidism (Group 3). MEASUREMENTS Thyroid stimulating antibody (TSAb) activity was measured as the amount of cyclic adenosine monophosphate (cAMP) produced by cultured FRTL-5 cells, and TSBAb activity as the inhibition of cAMP produced in response to 100 mU/l bovine TSH. RESULTS At about 3 months after 131I treatment, TSAb activity increased significantly in Groups 2 and 3, but did not change in Group 1. In contrast, TSBAb activity in Group 1 increased significantly and was positive in 6 patients at that time. At 12–18 months after 131I treatment, TSBAb activity tended to decrease and remained positive in 3 patients but became negative in 3 patients. It did not change in the patients in Groups 2 and 3. The patients in Group 1 were treated with levothyroxine, 75–125 μg/day. Levothyroxine was discontinued in the 3 patients whose TSBAb activity disappeared. Two of them remained euthyroid, and 1 became hypothyroid. CONCLUSION Results indicate that the hypothyroidism that develops within a short time after 131I treatment may be caused by TSBAb activity. Thyroid function may be recovered when TSBAb activity disappears. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text